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A SURVEY OF PUBLIC HOSPITAL PHARMACISTS 
IN SINGAPORE ON THEIR VIEWS ABOUT
‘THE FORMULARY’ AND ITS
DECISION-MAKING PROCESS
Roy A, Li SC
National University of Singapore, Singapore, Singapore
OUR PREMISE: If the expectation is “A formulary must
help control drug costs but not just promote cheap drugs
(i.e., compromise on quality of care)”, there clearly exists
a need for pharmacoeconomics in formulary decision-
making. OBJECTIVES: To understand if such expecta-
tion and need exist in Singapore, and how confident
pharmacists would be if asked to use pharmacoeconom-
ics to aid their decision-making. METHOD: After having
obtained consent from the respective pharmacy manag-
ers, survey forms were circulated to all pharmacists in the
5 major public hospitals of Singapore. If after 2–3 weeks,
the response rate was lower than 50% a reminder (via
e-mail) and a second circulation of the questionnaire was
made. In the event of any clarification(s) being required,
the respondent was contacted over phone. RESULTS
AND CONCLUSION: With a response rate that ranged
from 50% to 85% in the individual hospitals and an
overall average of 64% (70 of 110 identified pharma-
cists responded) our findings delineated the following
picture in Singapore. Formulary restriction is the best
method to control drug costs (57%). However, it should
not be a list of cheapest alternatives (90 %) but should
ideally promote the use of the best drug (71%) while also
controlling the hospital budget (57%). Though what fac-
tors are involved in the current formulary decision-mak-
ing process are not known (49% have no knowledge),
drug effectiveness (64%) as opposed to acquisition cost
(5%) will be considered as the most important factor by
the pharmacists if they were to decide on the formulary.
However, only 1% felt very confident about being able to
use pharmacoeconomics to aid their decision-making, if
asked to do so. There is therefore, a definite but unstated
need for use of pharmacoeconomics in the formulary set-
ting; however, there is clearly a lack of capability to fulfill
the need.
PHP16
THE VALUE OF VARIOUS FORMS OF EVIDENCE 
IN DRUG FORMULARY DECISION MAKING
Morris L1, Aikin K2
1Louis A. Morris & Associates, Dix Hills, NY, USA; 2Food and 
Drug Administration, Rockville, MD, USA
INTRODUCTION: The study examined the perceived
value of different forms of evidence (i.e., randomized
controlled trials and retrospective cohort analyses study
designs) among physicians and pharmacists (N  780).
Research participants read three abstracts (for each of
three fictitious drugs) that varied type of claim (cost,
cost-effectiveness, and effectiveness) and study design.
They rated the perceived value of the study in determin-
ing formulary recommendations on seven items. METH-
ODS: Factor analysis was used to derive weights for a
single measure of value that ranged from 0.735 (low
value) to 5.145 (high value). RESULTS: Four-way ANO-
VAs indicated that cost-effectiveness (mean  3.19) and
effectiveness (mean  3.11) data were of more value than
cost data (mean  2.84, p  .0001). Also, formulary-
affiliated physicians (mean  3.10) found the studies to
be of more value than hospital pharmacy directors (mean 
2.93, p  .02). A significant two-way interaction indi-
cated that pharmacy directors valued retrospective co-
hort analyses more than randomized trials regardless of
type of claim. In contrast, physicians valued randomized
trials more than retrospective cohort analyses (p  .001).
Manipulation checks indicated some difficulty identifying
the purpose of individual studies. While most respon-
dents could correctly identify cost-effectiveness and effec-
tiveness studies (between 77% and 92% correctly identi-
fied these studies), there was confusion regarding cost
studies. Almost half of the participants (between 42%
and 57%) characterized these studies (which were de-
scribed as “cost-minimization” analyses) as cost-effec-
tiveness studies. Pharmacy directors (49%) were more
likely to mischaracterize the cost-minimization studies
compared to the physician groups (approximately 40%
of these groups) (chi square  20.29, p  .02). CON-
CLUSIONS: The results suggest that the multidisci-
plinary make-up of formulary committees is important to
assure the incorporation of multiple forms of evidence in
decision-making. Also, more attention to the study design
is essential to evaluate the value of various forms of evi-
dence for formulary decisions.
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OBJECTIVE: This study compares patient outcomes in
the mechanically ventilated ICU patient by patient demo-
graphics, hospital characteristics and drug therapy. METH-
ODS: Data collected from 42 hospitals included patient
demographics, disease severity, sedatives/analgesics ad-
ministered, hospital type/size, days hospitalized and dis-
charge status. RESULTS: 622 patients were studied (48%
female, mean APACHE score  21.7, 31% with care
plans). Only 50% of patient episodes for ICU sedation
greater than 24 hours were treated with lorazepam
(guideline recommended drug for long-term sedation).
94% of patients received recommended analgesics. Pa-
tients in community hospitals had fewer ICU days (9.31
versus 11.05) and total hospital days (14.14 versus
16.96) compared to teaching hospitals. Patients receiving
midazolam or orazepam had shorter hospital stays (13.7
and 15.5 days respectively) compared to propofol pa-
